Weekly Digest - September 2026
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - September 2026
23 September 2026: SOTIO advances SOT106 with dual FDA designations for Sarcoma
- SOTIO announced that SOT106 received two additional FDA designations: Orphan Drug Designation for soft tissue sarcoma and Fast Track Designation for osteosarcoma, bringing both designations to each indication
- The designations were supported by preclinical evidence, including patient-derived xenograft models of osteosarcoma and STS showing strong antitumor activity, tumor regression and favorable tolerability; SOT106 has not yet entered clinical testing, with a first-in-human study planned for later in 2026
- The regulatory recognition addresses a major unmet need in sarcoma, where patients have limited targeted treatment options and treatment continues to rely heavily on chemotherapy, particularly in osteosarcoma and advanced STS
- SOT106 is an LRRC15-directed ADC that uses LigaChem Biosciences’ ConjuAll site-specific conjugation technology and a beta-glucuronidase-cleavable linker to deliver the microtubule inhibitor MMAE, with the membrane-permeable payload also enabling a bystander effect
- Strategically, the dual FDA designations strengthen SOT106’s regulatory positioning across multiple sarcoma subtypes ahead of clinical entry, while its LRRC15-targeted design and preclinical activity support SOTIO’s strategy of developing a differentiated next-generation ADC for mesenchymal tumors
